JT Stratford LLC’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.46M Buy
4,850
+428
+10% +$434K 0.57% 39
2025
Q4
$4.75M Buy
4,422
+210
+5% +$201K 0.61% 33
2025
Q3
$3.21M Buy
4,212
+898
+27% +$668K 0.43% 50
2025
Q2
$2.58M Sell
3,314
-77
-2% -$59.8K 0.39% 50
2025
Q1
$2.8M Sell
3,391
-345
-9% -$287K 0.5% 35
2024
Q4
$2.88M Sell
3,736
-124
-3% -$103K 0.47% 37
2024
Q3
$3.42M Sell
3,860
-332
-8% -$298K 0.58% 30
2024
Q2
$3.8M Buy
4,192
+87
+2% +$69.6K 0.71% 27
2024
Q1
$3.19M Sell
4,105
-406
-9% -$289K 0.64% 29
2023
Q4
$2.63M Sell
4,511
-691
-13% -$403K 0.6% 35
2023
Q3
$2.79M Sell
5,202
-479
-8% -$247K 0.72% 27
2023
Q2
$2.66M Buy
5,681
+1,101
+24% +$462K 0.72% 30
2023
Q1
$1.57M Sell
4,580
-129
-3% -$43.5K 0.45% 61
2022
Q4
$1.72M Buy
+4,709
New +$1.67M 0.55% 48
2021
Q3
Sell
-944
Closed -$217K 220
2021
Q2
$217K Sell
944
-240
-20% -$48.2K 0.07% 196
2021
Q1
$221K Buy
+1,184
New +$232K 0.08% 185
2020
Q3
Sell
-1,559
Closed -$256K 166
2020
Q2
$256K Buy
+1,559
New +$239K 0.13% 128

Other funds holding LLY

JT Stratford LLC's LLY Position: Q1 2026 in Review

JT Stratford LLC increased its Eli Lilly (LLY) stake by 9.7% in Q1 2026, buying an estimated $434K and bringing the position to 4,850 shares worth $4.46M. The position accounts for 0.57% of the portfolio, ranked #39.

JT Stratford LLC first reported a position in LLY in Q2 2020 and has held it in 17 quarters since. The position peaked at $4.75M in Q4 2025. 4,355 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • JT Stratford LLC held 4,850 shares of Eli Lilly worth $4.46M as of Q1 2026.
  • JT Stratford LLC bought 428 Eli Lilly shares in Q1 2026, an estimated $434K.
  • Eli Lilly made up 0.57% of JT Stratford LLC's portfolio in Q1 2026, its #39 holding.
  • JT Stratford LLC first reported a position in Eli Lilly in Q2 2020 and has held it in 17 quarters since.
  • JT Stratford LLC's Eli Lilly position peaked at $4.75M in Q4 2025.
  • 4,355 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on JT Stratford LLC's 13F filing for Q1 2026, filed 15 May 2026.